Expertos Invitados





A RELAÇAO APO-B/APO-AI, MAS NAO OS POLIMORFISMOS DAS APOLIPOPROTEINAS AI-CIII ASSOCIAM-SE A DOENÇA ARTERIAL CORONARIANA PREMATURA

(especial para SIIC © Derechos reservados)
A relação apo-B/apo-AI aumentada e fatores de risco clássicos associaram-se à doença arterial coronariana prematura. Polimorfismos no cluster gênico AI-CIII não influenciaram sua ocorrência.
oliveiraizar9.jpg Autor:
Maria cristina De oliveira izar
Columnista Experto de SIIC

Institución:
Universidade Federal de São Paulo

Artículos publicados por Maria cristina De oliveira izar
Recepción del artículo
9 de Marzo, 2006 		Aprobación
29 de Marzo, 2006
Primera edición
27 de Junio, 2006 		Segunda edición, ampliada y corregida
7 de Junio, 2021

A RELAÇAO APO-B/APO-AI, MAS NAO OS POLIMORFISMOS DAS APOLIPOPROTEINAS AI-CIII ASSOCIAM-SE A DOENÇA ARTERIAL CORONARIANA PREMATURA

Resumen
Este estudo avaliou associações entre fatores de risco clássicos e emergentes na doença arterial coronariana (DAC) prematura. Métodos: Estudo caso-controle incluiu 112 indivíduos com DAC prematura e 112 controles, pareados por sexo e idade. Lípides e apolipoproteínas (AI e B), marcadores da hemostasia (fibrinogênio, dímero-D, fator de Von Willebrand, fator VII e inibidor do ativador do plasminogênio-1), e polimorfismos do cluster gênico AI-CIII foram examinados em jejum após intervenção nutricional (NCEP III). Resultados: A hipertensão arterial, o diabetes, o fumo pregresso e o antecedente familiar de DAC prematura foram mais prevalentes na DAC prematura (p < 0.001), e esses pacientes apresentaram níveis maiores de colesterol total, LDL-C, triglicérides e de apo-B (p < 0.01) e menores de HDL-C e apo-AI (p < 0.001), além de maior relação apo-B/apo-AI. O fibrinogênio plasmático e o dímero-D (p < 0.02) foram maiores na DAC prematura. Não se observaram associações entre os polimorfismos estudados e a DAC prematura. A chance da DAC prematura associou-se à relação desfavorável apo-B/apo-AI (OR = 23.8), ao diabetes (OR = 6.1), à hipertensão arterial (OR = 3.9), ao fumo pregresso (OR = 3.7) e ao antecedente familiar de DAC prematura (OR = 2.5). Conclusão: Fatores de risco modificáveis associam-se à doença coronariana prematura e ações preventivas ambientais de impacto poderão reduzir os desfechos cardiovasculares nessas populações.

Palabras clave
fatores de risco, lípides, apolipoproteínas, hemostasia, polimorfismos, genética


Artículo completo
(castellano)
Extensión:  +/-5.24 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

APO-B/APO-AI RATIO, BUT NOT THE POLYMORPHISMS IN THE APO AI-CIII GENE CLUSTER ARE ASSOCIATED WITH EARLY CORONARY ARTERIAL DISEASE

Abstract
This study was aimed to evaluate associations of classic and emergent risk factors and early coronary heart disease (CHD). Methods: A case-control study included 112 individuals with early CHD and 112 controls, paired by age and sex. Lipids and apolipoproteins (AI and B), markers of hemostasis (fibrinogen, D-dimer, von Willebrand factor, factor VII and PAI-1), and polymorphisms of AI-CIII gene cluster were examined in the fasting state after nutrition counseling (NCEP III). Results: Hypertension, diabetes, prior smoking and family history of premature CHD were more prevalent in early CHD (p < 0.001), and these patients presented higher serum total cholesterol, LDL-C, triglycerides, and apo-B (p < 0.01), and lower HDL-C and apo-AI (p < 0.001) than controls. Elevated Apo-B/apo-AI ratio was seen in early CHD, as well. Fibrinogen and D-dimer (p < 0.02) were higher in premature CHD. No associations were found between the studied polymorphisms and early CHD. Risk of early CHD was associated with increased apo-B/apo-AI ratio (OR = 23.8), diabetes (OR = 6.1), hypertension (OR = 3.9), prior smoking (OR = 3.7) and family history of premature CHD (OR = 2.5). Conclusions: Modifiable risk factors are associated with early CHD, and preventive actions to reduce its impact might reduce cardiovascular events in these populations.

Key words
risk factors, lipids, apolipoproteins, hemostasis, polymorphisms, genetics

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Cardiología
Relacionadas: Bioquímica, Diagnóstico por Laboratorio, Medicina Interna



Comprar este artículo
Extensión: 5.24 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Maria Cris de Oliveira Izar, Universidade Federal de São Paulo, 04039-001, Rua Pedro de Toledo 458, Vila Clementino, San Pablo, Brasil
Patrocinio y reconocimiento:
Agradecimentos: Este trabalho recebeu auxílio financeiro da Fapesp (Fundação de Amparo à Pesquisa do Estado de São Paulo), nº 98/02174-4.
Bibliografía del artículo
1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349:1269-76.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1498-504.
3. World Heath Organization. The World Health Report 2002. Geneva: World
Health Organization, 2002.
4. Assmann G, Schulte H, Von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124 Suppl:S11-20.
5. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14:54-9.
6. Assmann G, Cullen P, Heinrich J, Schulte H. Hemostatic variables in the prediction of coronary risk: results of the 8 year follow-up of healthy men in the Munster Heart Study (PROCAM). Prospective Cardiovascular Munster Study. Isr J Med Sci 1996; 32:364-70.
7. Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998; 140:271-80.
8. Yusuf S, Hawken S, Ounpuu S, e col; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-52.
9. Greenland P, Knoll MD, Stamler J, e col. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003; 290:891-7.
10. Motulsky AG, Brunzell JD. Genetics of coronary artery disease. In: King RA, Rotter JI, Motulsky AG, eds. The Genetic Basis of Common Disease 2nd ed. New York, NY: Oxford University Press; 2002:105-126.
11. Milewicz DM, Seidman CE. Genetics of cardiovascular disease. Circulation 2000; 102:IV-103-IV-111.
12. Talmud PJ, Hawe E, Martin S, e col. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 2002; 11:3039 -3046.
13. Mar R, Pajukanta P, Allayee H, e col. Association of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Circ Res 2004; 94:993-9.
14. Allayee H, Aouizerat BE, Cantor RM, e col. Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype. Am J Hum Genet 1998; 63:577-585.
15. Russo GT, Meigs JB, Cupples LA, e col. Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham Offspring study. Atherosclerosis 2001; 158:173-181.
16. Stocks J, Paul H, Galton D. Haplotypes identified by DNA restriction-fragment-length polymorphisms in the A-1 C-III A-IV gene region and hypertriglyceridemia. Am J Hum Genet 1987; 41:106 -118.
17. Tahvanainen E, Pajukanta P, Porkka K, e col. Haplotypes of the ApoA-I/C-III/A-IV gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1998; 18:1810 -1817.
18. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
19. Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. III Diretrizes sobre Dislipidemias e Diretriz de Prevenção de Aterosclerose. Arq Bras Cardiol 2001; 77(supl. III):S4-8.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
21. Clauss A. Quick method to estimate fibrinogen by a functional clotting assay. Acta Haematol 1957; 17:237-46.
22. Dallinga-Thie GM, Bu X, van Linde-Sibenius Trip M, Rotter JI, Lusis AJ, De Bruin TWA. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res 1996; 37:136-47.
23. Hosmer DW, Lemeshow S. Applied Logistic Regression. John Wiley & Sons. New York, NY, 1989; 307pp.
24. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358:2026-33.
25. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD.The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004; 42:1355-63.
26. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104:2746-53.
27. Keavney B, Palmer A, Parish S, e col; International Studies of Infarct Survival (ISIS) Collaborators. Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations, and coronary disease risk. Int J Epidemiol 2004; 33:1002-13.
28. Casani L, Sanchez-Gomez S, Vilahur G, Badimon L. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thromb Haemost 2005; 94:1035-41.
29. Kothari SA, Le MK, Gandhi PJ. Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications. J Thromb Thrombolysis 2003; 15:217-25.
30. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338:1650-6.
31. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-31.
32. Hambrecht R, Gielen S. Essay: Hunter-gatherer to sedentary lifestyle. Lancet 2005; 366 Suppl 1:S60-1.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008